🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Correlation Study of Atrophic Gastritis and Dyspepsia Symptoms

Recruitingn/aAges 18 Years - 75 YearsAllThe Third Affiliated hospital of Zhejiang Chinese…
NCT07250308 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Background: Dyspepsia is a common gastrointestinal complaint globally, affecting approximately 21.8% of the population. Among patients presenting with dyspeptic symptoms, over 80% are diagnosed with functional dyspepsia (FD), while approximately 16% are found to have chronic atrophic gastritis (CAG). CAG represents an important precancerous condition in the gastric cancer cascade, yet the relationship between pathologically confirmed CAG and dyspeptic symptoms remains poorly understood. The significant symptom overlap between CAG and FD creates diagnostic challenges in clinical practice. Study Objectives: The primary objective is to determine whether there are significant differences in the prevalence and severity of dyspeptic symptoms (including epigastric pain, burning sensation, early satiety, and postprandial fullness) between patients with pathologically confirmed CAG and those w

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age 18-75 years 2. Recent gastroscopic examination (within 1 year) suggesting chronic atrophic gastritis 3. Underwent standardized pathological examination (5-point gastric mucosa biopsy according to the "Updated Sydney System" including antrum, body, and angle) 4. Signed informed consent Exclusion Criteria: 1. Gastric cancer or suspected malignant lesions 2. Concomitant significant other gastrointestinal diseases (e.g., ulcer, Barrett's esophagus, etc.) 3. Autoimmune gastritis 4. Unable to complete questionnaire survey
💊

What it tests

  • Not listed
📍

Where

1 site
The Third Affiliated Hospital of Zhejiang Chinese Medicinal University
Hangzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy